drugset / Trial / NCT00120692

Treatment for Patients Suffering From Anemia Due to Chemotherapy

NCT00120692 ↗

Phase 2 Completed Amgen
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to validate a Patient Satisfaction Questionnaire for Anemia Treatment (PSQ-AT) in female breast cancer patients treated with darbepoetin alfa or recombinant human erythropoietin (rHuEPO) for anemia due to chemotherapy.

Timeline

Start
2002-10
Primary completion
—
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic 200 ug —
Subject recombinant human erythropoietin Protein / enzyme biologic 40000 iu —

Indications